North America Biologics Market – Size, Outlook, Trends and Forecast (2024 – 2032)

Biologics are the new class of protein-based therapeutics that are produced using living organisms, including plants, animals, and microorganisms such as yeast & bacteria. Biologics are used to treat diseases like cancer, rheumatoid arthritis and many more rare diseases. Any medical product that is originated from living organisms is considered as biological products.

North America Biologics Market Size & Growth:

The North America biologics market was valued to be nearly $XX billion in 2017 and is expected to reach over $XX billion by the end of 2025 with a CAGR of almost XX% during the North America biologics market forecasts period 2019-2025. The initial stage challenge for biologics market is a stringent regulatory process & high capital investment decides the market. Biologics drugs are highly complex and required to control & maintain throughout the development & production process. This regulated environment & quality control procedures involve huge capital investment. Additionally, biologics are most susceptible to light, heat conditions, and need an extremely promising environment that is not available uniformly across the globe. Stringent regulatory policies and high-capital investment coupled with limited patient access to reasonable biologics mainly in the developing countries owing to the increasing control and cost for accessing biologics are likely to obstruct the growth of the North America biologics market growth. Key drivers driving North America biologics market growth are increasing capital investment from critical players, rising prevalence of chronic diseases, growing demand & higher acceptability for innovative therapies and others. Rising prevalence of chronic diseases is driving the North America market. Increase in population & changes in social behaviour is contributing to a steady rise in these common & costly long-term health problems. The middle class is increasing and the urbanisation fast-tracking, adopting a more inactive lifestyle. This is increasing obesity rates and leading many diseases with diabetes on top. Based on the World Health Organization report, chronic disease prevalence is expected to rise by 57% by the year 2020. Emerging markets will be hardest hit, as population growth is expected to be most significant in developing nations. Based on the North America biologics market outlook, cancer application market size is estimated to proliferate. According to the North America biologics market analysis, North America biologics market size will increase during the forecast period 2019-2025.

North America Biologics Market Share:                                                                                     

North America biologics market is classified by types such as by products, by applications and by geography. By the product, the market in monoclonal antibodies segment of the biologics market is estimated to grow at the fastest CAGR during the forecast period. Antibodies are made by different immune cells that are all clones of a unique parent cell. These antibodies have a monovalent affinity and bind to the same epitope to treat cancer.

Regarding application, the market in cancer application of the biologics market is estimated to grow at the fastest CAGR during the forecast period. This growth can be due to increasing demand for biologics in the treatment of cancer, and this treatment is used to kill cancer cells by body immune system. Concerning geography, the market is segmented into U.S, Canada & Mexico. The U.S is predicted to be a dominant market in the biologics market during 2019 – 2025. Major Biologics companies are based in the U.S. Also, the region has the significant biologics teams in the world and consequently produces high demand for biologics. Canada will be the fastest growing market regarding biologics. Increasing capital investments from critical players is boosting the biologics market.

North America Biologics Market Trends:

• October 2017, US FDA accepted F. Hoffmann-La Roche Ltd supplemental Biologics License Application for Avastin as a front-line treatment for women, with advanced ovarian cancer.
• August 2018, while facing authorisations, Samsung ups its investment in biologics.

North America Biologics Market Research Report:

• An executive summarycondensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
• To have a complete market analysis through industry value chain analysis, Porter’s five, PESTLE, SWOTanalysis, and Y-o-Y analysis.
• Regional and North America diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year–On–Year
• Identifying DROC in the current market and their impact on altering the market dynamics.
• Competitive landscape analysis to identify the merger and acquisition which will have a comparative financial analysis with significant competitors.
• Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.
• Identify the latest developments, market shares and strategies that are employed by the major market players, such as
  • Gilead Science.
  • Celgene
  • Merck & Co
  • Novo Nordisk
  • Biogen
  • Teva
  • CSL
  • Shire
  • Allergan Plc.
  • Samsung biologics
  • Mylan
  • Astellas Pharma Inc.